ClinConnect ClinConnect Logo
Search / Trial NCT05375968

Splanchnic Venous Capacitance in Postural Tachycardia Syndrome

Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · May 10, 2022

Trial Information

Current as of September 02, 2025

Recruiting

Keywords

Glucose Dependent Insulinotropic Polypeptide (Gip)

ClinConnect Summary

This clinical trial is studying Postural Tachycardia Syndrome (POTS), a condition that affects many young people and causes symptoms like dizziness and rapid heart rate when standing, especially after meals. The researchers want to understand how eating carbohydrates, like those in sugary foods, might make these symptoms worse by causing more blood to pool in the stomach area. They are particularly interested in how certain natural substances released during digestion could affect blood flow and symptoms in POTS patients compared to healthy individuals.

To be eligible for this trial, participants need to be between 18 and 50 years old and either diagnosed with POTS or healthy with no serious medical history. The study will involve some tests before and after participants eat a glucose drink, and they will be monitored for changes in blood flow and symptoms. It's important to know that those with certain health issues, like diabetes or heart problems, cannot participate. This study aims to help improve understanding of POTS and potentially lead to better treatment options for those affected.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Between 18 and 50years of age
  • Cases: Diagnosis of POTS with presyncope symptoms after meals Or
  • Controls:
  • With no significant past medical history, non-smokers and not on chronic medications.
  • Body mass index (BMI) between 18.5 to 29.9 kg/m2
  • If pre-menopausal women: must have regular menstrual cycle.
  • Exclusion Criteria:
  • BMI above ≥30 kg/m2
  • Irregular menstrual cycle
  • Intolerance to CPAP.
  • Chronic use of acetaminophen
  • Heart problems: myocardial infarction, angina, heart failure, stroke
  • Undergone any heart related procedures or stents or on pacemaker.
  • Uncontrolled hypertension.
  • Type 1 or type 2 diabetes mellitus
  • Pregnant or breast-feeding women.
  • Impaired liver function
  • Impaired Kidney function test.
  • Anemia (Hematocrit\<34%).
  • Ongoing substance abuse.
  • Subjects with abnormal EKG
  • History of seizures.
  • Diagnosed with neuropathy due to any reason
  • History of neck surgery.
  • Smoker,
  • On statin therapy for high cholesterol
  • Rheumatoid arthritis.
  • On oral corticosteroids,
  • Current infections
  • Documented of moderate decrease in blood volume

About Vanderbilt University Medical Center

Vanderbilt University Medical Center (VUMC) is a leading academic medical center located in Nashville, Tennessee, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, VUMC integrates cutting-edge scientific inquiry with patient-centered care, supporting a diverse array of studies aimed at enhancing medical knowledge and improving treatment outcomes. With a robust infrastructure and a multidisciplinary team of experts, VUMC fosters collaboration across various fields, ensuring the highest standards of safety and ethical considerations in its research endeavors. Through its dedication to medical discovery and education, VUMC plays a pivotal role in shaping the future of medicine.

Locations

Nashville, Tennessee, United States

Patients applied

0 patients applied

Trial Officials

Cyndya Shibao, M.D

Principal Investigator

Vanderbilt University Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials